10-Q: Quarterly report
Codex DNA GAAP EPS of -$0.28 Beats by $0.13, Revenue of $9.47M Beats by $2.27M
Telesis Bio (NASDAQ:DNAY) Trading 11.4% Higher
Telesis Bio, Inc. (NASDAQ:DNAY – Get Rating) shares traded up 11.4% on Monday . The company traded as high as $1.95 and last traded at $1.85. 49,762 shares changed hands during mid-day trading, a decl
Telesis Bio Pre-Announces Preliminary Fourth Quarter Financial Results
-- Record revenue of $9M in 4QFY22; Increase of 191% over 4QFY21 -- BioXp® Revenue increased by 131% to $3M, in 4QFY22 over 4QFY21 -- Successful achievement of first technical milestone with Pfizer le
Codex DNA Sees 4Q Rev $9M >DNAY
Codex DNA Sees 4Q Rev $9M >DNAY
Reviewing Telesis Bio (NASDAQ:DNAY) and Arrayit (OTCMKTS:ARYC)
Arrayit (OTCMKTS:ARYC – Get Rating) and Telesis Bio (NASDAQ:DNAY – Get Rating) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of
News On Codex DNA Inc. (DNAY) Now Under TBIO
News On Codex DNA Inc. (DNAY) Now Under TBIO
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersQuotient (NASDAQ:QTNT) stock moved upwards by 114.0% to $0.49 during Thursday's pre-market session. The market value of their outstanding shares is at $1.7 million. Baudax Bio (NASDAQ:BXRX) sha
Reviewing Bionano Genomics (NASDAQ:BNGO) & Telesis Bio (NASDAQ:DNAY)
Bionano Genomics (NASDAQ:BNGO – Get Rating) and Telesis Bio (NASDAQ:DNAY – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on
Critical Comparison: Bionano Genomics (NASDAQ:BNGO) Versus Telesis Bio (NASDAQ:DNAY)
Bionano Genomics (NASDAQ:BNGO – Get Rating) and Telesis Bio (NASDAQ:DNAY – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based o
Stocks That Hit 52-Week Lows On Wednesday
 Wednesday saw 219 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Salesforce (NYSE:CRM).Versus Syste
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 167 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Salesforce (NYSE:CRM) was the largest, in terms of market cap, to set a new 52-week low.The co
Telesis Bio, Inc. (NASDAQ:DNAY) Short Interest Up 12.3% in October
Telesis Bio, Inc. (NASDAQ:DNAY) was the recipient of a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 265,400 shares, an increase of 12.3% from the October 15th total of 236,300 shares.
FY2022 EPS Estimates for Telesis Bio, Inc. Boosted by Analyst (NASDAQ:DNAY)
Telesis Bio, Inc. (NASDAQ:DNAY) – Equities research analysts at KeyCorp upped their FY2022 earnings per share estimates for Telesis Bio in a note issued to investors on Tuesday, November 8th. KeyCorp analyst P. Knight now forecasts that the company will earn ($1.82) per share for the year, up from their previous estimate of ($1.85).
Codex DNA (DNAY) Reports Q3 Loss, Tops Revenue Estimates
KeyBanc Capital Markets Adjusts Price Target on Codex DNA to $5 From $8, Maintains Overweight Rating
09:41 AM EST, 11/09/2022 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
Codex DNA Price Target Cut to $5.00/Share From $8.00 by Keybanc
Codex DNA Price Target Cut to $5.00/Share From $8.00 by Keybanc
Codex DNA Is Maintained at Overweight by Keybanc
Codex DNA Is Maintained at Overweight by Keybanc
Codex DNA Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 11/09/2022 199.4% Keybanc $8 → $5 Maintains Overweight 03/28/2022 379.04% Keybanc $30 → $8 Maintains Overw
Keybanc Maintains Overweight on Codex DNA, Lowers Price Target to $5
Keybanc analyst Paul Knight maintains Codex DNA (NASDAQ:DNAY) with a Overweight and lowers the price target from $8 to $5.
No Data